Search results (1331)
« Back to PublicationsMbd3/NuRD controls lymphoid cell fate and inhibits tumorigenesis by repressing a B cell transcriptional program.
Loughran SJ. et al, (2017), The Journal of Experimental Medicine, 214, 3085 - 3104
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Harrison CN. et al, (2017), Blood, 130, 1889 - 1897
Characterisation of the changing genomic landscape of metastatic melanoma using cell free DNA.
Cutts A. et al, (2017), NPJ genomic medicine, 2, 25 - 25
Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)
Weber J. et al, (2017), ANNALS OF ONCOLOGY, 28
Allogeneic Hematopoietic Cell Transplantation Outcomes After Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (CA209-039 and CheckMate 205)
Carlo-Stella C. et al, (2017), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 17, S326 - S327
Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial
Jaeger U. et al, (2017), ONCOLOGY RESEARCH AND TREATMENT, 40, 13 - +
Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis
Olszanski AJ. et al, (2017), ANNALS OF ONCOLOGY, 28
PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors
Garcia-Corbacho J. et al, (2017), ANNALS OF ONCOLOGY, 28
Single cell analysis of normal and leukemic hematopoiesis.
Povinelli BJ. et al, (2017), Molecular aspects of medicine
Staging gastric cancer with F-18-FDG PET-CT identifies frequent unsuspected metastases and patients at high risk of incurable disease, early recurrence and death
Findlay J. et al, (2017), BRITISH JOURNAL OF SURGERY, 104, 6 - 6
Validation of metabolic nodal response and a simple risk score to predict early recurrence and death after surgery for oesophageal cancer
Findlay J. et al, (2017), BRITISH JOURNAL OF SURGERY, 104, 56 - 57
Equivalence of BCSH and WHO diagnostic criteria for ET.
Harrison CN. et al, (2017), Leukemia, 31, 1660 - 1660
Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation.
Mead AJ. et al, (2017), The Journal of experimental medicine, 214, 2005 - 2021
COMBINATION OF DEEP PHENOTYPING AND TARGETED NEXT GENERATION SEQUENCING AS A DIAGNOSTIC TOOL IN CHILDREN WITH SUSPECTED MDS
Louka E. et al, (2017), HAEMATOLOGICA, 102, 265 - 265
COMPARISONS OF PATIENT MANAGEMENT IN MYELOPROLIFERATIVE NEOPLASM PATIENTS IN THE UK VS REST OF WORLD: ANALYSIS FROM THE INTERNATIONAL LANDMARK SURVEY
Harrison C. et al, (2017), HAEMATOLOGICA, 102, 813 - 814
COMPARISONS OF SYMPTOM BURDEN IN MYELOPROLIFERATIVE NEOPLASM PATIENTS IN THE UK VS REST OF WORLD: ANALYSIS FROM THE INTERNATIONAL LANDMARK SURVEY
Harrison C. et al, (2017), HAEMATOLOGICA, 102, 815 - 816
DEVELOPMENT OF A NEW HAEMATOLOGICAL MALIGNANT PATIENT-REPORTED OUTCOME MEASURE FOR USE IN CLINICAL PRACTICE: HM-PRO
Goswami P. et al, (2017), HAEMATOLOGICA, 102, 602 - 602
DISRUPTION OF HAEMATOPOIETIC STEM CELL HETEROGENEITY IN A MOUSE MODEL OF MYELOPROLIFERATIVE NEOPLASM
Norfo R. et al, (2017), HAEMATOLOGICA, 102, 149 - 150
IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN
Hiddemann W. et al, (2017), HAEMATOLOGICA, 102, 314 - 314